Article Figures & Data
Additional Files
Data Supplement
- Supplemental Data -
Supplementary Table 1A - Primer sequences for RT-qPCR.
Supplementary Table 1B - Antibodies used for Western blot.
Supplementary Table 2 - Extracellular dFdU and intracellular dFdCTP concentrations following 24 hours gemcitabine (10 or 100 μM) incubation with or without 200 μM tetrahydrouridine.
Supplementary Figure 1 - Stability of 10 μM gemcitabine (dFdC) in Dulbecco’s modified Eagles medium with horse serum at 4 °C, room temperature (RT) and 37 °C. dFdU concentrations relative to the sum of dFdC and dFdU concentrations ([dFdU]/([dFdC]+[dFdU]), %), was used as a measure of CDA-activity.
Supplementary Figure 2 - Concentrations of gemcitabine metabolites following 60 minutes incubation with 10 or 100 μM gemcitabine ± 200 μM tetrahydrouridine (THU), a cytidine deaminase inhibitor.
Supplementary Figure 3 - Western blots of protein expression of selected proteins involved in the transport* and metabolism of gemcitabine in BxPC-3, MIA PaCa-2 and PANC-1.
Supplementary Figure 4 - Viability of BxPC-3 (high CDA expression) and PANC-1 (low CDA expression) following 60 minutes or 24 hours incubation with 10 μM gemcitabine and/or 200 μM tetrahydrouridine.
- Supplemental Data -